



DARZALEX™
daratumumab
concentrate for solution for infusion



janssen  **Oncology**

PHARMACEUTICAL COMPANIES OF *Johnson & Johnson*

For distribution by healthcare professionals to patients prescribed with DARZALEX™ only.

Please consult your doctor or healthcare professional if you have any questions.

TREATING MULTIPLE MYELOMA WITH **DARZALEX™**¹

What is **DARZALEX™** used for?¹

DARZALEX™ is used to treat adults with multiple myeloma. You have been prescribed DARZALEX™ because you have been newly diagnosed with multiple myeloma or have received prior treatments for this condition.¹

DARZALEX™ indications:¹

DARZALEX™ in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.

DARZALEX™ in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

DARZALEX™ in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant.

DARZALEX™ in combination with bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

DARZALEX™ as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to a PI and an immunomodulatory agent.

For distribution by healthcare professionals to patient prescribed with DARZALEX™ only.
Please consult your doctor or healthcare professional if you have any questions.


HOW DOES **DARZALEX™** WORKS?²

DARZALEX™ is an anti-cancer medicine. It contains a substance called daratumumab. Daratumumab belongs to a group of medicines called monoclonal antibodies.²

Monoclonal antibodies work by directly attaching to specific cancer cells in your body. This attachment can directly kill these cancer cells. Monoclonal antibodies also help your immune system to destroy cancer cells.²

DARZALEX™ targets and attaches to a protein called CD38. CD38 is found on the surface of certain types of cells (e.g. red blood cells) and is also found in high numbers on multiple myeloma cancer cells. Since DARZALEX™ targets the CD38 protein, it may also affect other cells with this protein on their surface.²

DARZALEX™ targets the CD38 protein.²



For distribution by healthcare professionals to patient prescribed with DARZALEX™ only.
Please consult your doctor or healthcare professional if you have any questions.

HOW IS DARZALEX™ GIVEN?^{1,2}

DARZALEX™ is given over several hours as a drip into a vein (intravenous infusion). DARZALEX™ is given in a hospital or infusion centre. Doctor will measure your patient's weight to determine the dose of DARZALEX™.²

DARZALEX™ may be given alone or together with other medicines used to treat multiple myeloma (with bortezomib, thalidomide and dexamethasone, or with bortezomib, melphalan and prednisone, or with lenalidomide and dexamethasone or with bortezomib and dexamethasone).^{1,2}



INFUSION

The first infusion of DARZALEX™ can take at least 7 hours.



Subsequent infusions are shorter, but will still take around 3–5 hours, so you will need to plan your infusion days.

Doctor will also prescribe medications for patient to take before and after each infusion to help prevent infusion-related reactions.¹

For distribution by healthcare professionals to patient prescribed with DARZALEX™ only.
Please consult your doctor or healthcare professional if you have any questions.



References:

1. DARZALEX™ Approved Prescribing Information Malaysia [CCDS v01 Jun2021].
2. DARZALEX™ Australia Consumer Medicine Information.
https://media.healthdirect.org.au/medicines/GuildLink_Information/281842/CMI/jccdarza10821.pdf. Accessed 07 January 2022. 18:00

For distribution by healthcare professionals to patient prescribed with DARZALEX™ only.
Please consult your doctor or healthcare professional if you have any questions.

For distribution by healthcare professionals to patient prescribed with DARZALEX™ only.
Please consult your doctor or healthcare professional if you have any questions.



Johnson & Johnson Sdn Bhd (Co. No. 3718-D)
© 2022 Johnson & Johnson Sdn. Bhd. All rights reserved.

Creation Number: CP-287456
Creation Date: March 2022